ArcticZymes Technologies (AZT)

TekBot · april 12, 2019, 10:00am

12/04-2019 11:59:17: (BIOTEC) Biotec Pharmacon ASA - Notice of Annual General Meeting

The Annual General Meeting in Biotec Pharmacon will be held on Wednesday 15. May
2019 at 11.00 CET at Hotell Continental, Stortingsgata 24/26, Oslo.
Please find the notice including agenda for the meeting and appendices attached
…

Vis børsmeldingen

to this disclosuere. The notice and appendicies will aslo be made available on
the Company’s homepage.

Shareholders who wish to attend the annual general meeting, in person or by
proxy, are requested to complete the registration form by Tuesday 14. May 2019
at 11.00 CET.
The annual report for 2018 is published in a seperate notice and made available
on www.biotec.no / investors / annual reports.
The nomination committees proposal is made public on www.biotec.no / about us /
corporate information / general meeting.
For further information, please contact:
Børge Sørvoll
CFO
+47 952 90187
[email protected]

http://www.netfonds.no/quotes/release.php?id=20190412.OBI.20190412S50

TekBot · april 24, 2019, 2:24pm

24/04-2019 16:23:38: (BIOTEC) Biotec Pharmacon ASA: Invitation to presentation of Q1 2019 results

TekBot · april 26, 2019, 12:24pm

26/04-2019 14:23:51: (BIOTEC) Biotec Pharmacon enters a distribution agreement for Woulgan® in Austria

Under the terms of the agreement, Publilog becomes an exclusive partner for distribution of Woulgan® to the Austrian market, with Biotec supporting Publilog’s marketing division. Publilog is a subsidiary of the Swiss based Publicare Group - a leading homecare company in the D-A-CH region.

Woulgan® is a premium-priced product targeting hard to heal wounds in the professional wound care market. Clinical experience with Woulgan® demonstrates significantly improved healing, less pain and improved comfort during the treatment period compared to most common therapies.
…

Vis børsmeldingen

This agreement align with the newly revised go-to-market strategy for Woulgan®, which focusses on launching and finding new partners in more countries.

Christian Jørgensen, CEO, said:

“We are pleased to see that Woulgan is generating interest in other parts of Europe, building on the increasing success we have been seeing in Germany. By entering into this new distribution agreement, we are delivering on our amended strategy to strenghten Woulgan’s market presence.”

Finn Ketler, VP Wound Care, said:

“By signing Publilog as our exclusive distributor in Austria, our market reach extends beyond our initial core markets. We expect that Woulgan will be reimbursed from January 1st, 2020, subject to regulatory processes, so sales are likely to start having an impact from the end of this year.”

Wolfgang Baumgartner, CEO Publilog GmbH, said

We are proud by signing the contract with Biotec Pharmacon because our intention is to bring new, unique products with high potential for the treatment of chronic wounds to the Austrian market. We started this way two years ago and continue now consistently.

-ENDS-

For more information, please contact:

Biotec Pharmacon
CEO Christian Jørgensen Tel: +47 47 79 24 57
Email: [email protected]
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / [email protected]
Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsoe to offer niche and high tech products in several biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsoe, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

About Biotec BetaGlucans

BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.

The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.

Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.

For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.

http://www.netfonds.no/quotes/release.php?id=20190426.Cision.20190426:BIT:6370:0

Ida · april 26, 2019, 12:43pm

Kan der komme et ekstra salg ud af den her aftale? Og hvor stort?

urban66 · april 26, 2019, 1:07pm

TekBot · april 30, 2019, 5:00am

30/04-2019 07:00:18: (BIOTEC) Biotec Pharmacon Q1 2019 Report

Tromsø, Norway, 30 April 2019 - Biotec Pharmacon (OSE: Biotec) announces its Q1
2019 results to 31 March 2019.
Highlights for Q1 2019
…

Vis børsmeldingen

· Group sales were up 4% to NOK 14.8 million (Q1 2018: NOK 14.2 million).
· Gross profit for the Group improved 23% to NOK 12.0 million (Q1 2018: NOK
9.7 million) due to improvements in all high margin areas.
· ArcticZymes had first quarter sales of NOK 7.9 million growing by 25% (Q1
2018: NOK 6.3 million).
· Woulgan® continues to generate recurring revenues with NOK 1.2 million for
the quarter, up 140% (Q1 2018: NOK 0.5 million), driven primarily by good sales
in the German market.
· Improvement in EBITDA to NOK -3.9 million (Q1 2018: NOK -5.1 million) as a
result of stronger sales in high margin areas.
· Cash-flow for the quarter was NOK -3.5 million (Q1 2018: -10.6 million).

CEO Christian Jørgensen comments:

“We have seen improvements across the business and, in particular, ArcticZymes
and Woulgan® sales have improved significantly compared to the same quarter last
year. Even though our business dynamics are not quarter-by-quarter, it is a
solid start to the year.”

“We have also continued to reduce our deficit through the combination of
stronger sales and tight cost control this quarter.”

“We continue to add customers in our various business segments, which is a
strong signal of the relevance of our products not only to our demanding direct
customers but also, more broadly, we are addressing unmet end-user needs.”

-Ends-

First Quarter 2019 Results Presentation and Webcast

A presentation by Biotec Pharmacon’s CEO, Christian Jørgensen, and CFO, Børge
Sørvoll, will take place today, 30 April 2019, at 08:30 am CET at Hotel
Continental, Stortingsgata 24/26, Oslo

The presentation can also be followed as a live webcast from Hegnar TV on
https://webtv.hegnar.no/presentation.php?webcastId=97815170. It will be possible
to post questions through the webcast console.

The results, report and presentation for the first quarter 2019 will be
available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company’s
homepage, www.biotec.no (https://protect-eu.mimecast.com/s/JfV3C1wDYUZ3XYhph
-Hn?domain=biotec.no) from 07:00 am on 30 April 2019.

Ends -

For more information, please contact:

Biotec Pharmacon
CEO Christian JørgensenCFO Tel: +47 47 79 24 57
Børge Sørvoll Tel: +47 95 29 01 87
[email protected]

Instinctif Partners
Melanie Toyne-Sewell / Tel: +44 207 457 2020
Christelle Kerouedan [email protected]
/Deborah Bell

About Biotec Pharmacon ASA

Biotec Pharmacon is a Norwegian life sciences company focused on specialized,
novel enzyme and immunomodulating beta-glucan technology.

The Biotec Pharmacon Group is creating value from innovation in life science
markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsø to offer niche and high tech products in several
biotech segments.

ArcticZymes develops, manufactures and commercialises novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans
addressing high unmet healthcare needs, such as chronic wound healing and as an
adjuvant in vaccines against certain types of cancer relapse.

Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec
Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre.

Biotec Pharmacon’s unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.biotec.no.

http://www.netfonds.no/quotes/release.php?id=20190430.OBI.20190430S12

Kronn · april 30, 2019, 6:00am

Salgene øker, men fra nesten null da, synst biotec er på rette vegen, det vil ta tid, men eg plukker stadig en og annen aksjen, men såpass seint at det foreløpig ikke er veldig mye å skryte av

Ida · april 30, 2019, 10:27am

Outlook for 2019 (fra præsentationen)

• Management expect revenue growth in the two focus areas – ArcticZymes and Woulgan® to be strongest in H2 – whilst reducing cash consumption.
• ArcticZymes – objectives are to grow business organically, launching new products, whilst seeking inorganic growth opportunities.
• Woulgan® – focus on increasing sales in existing and new territories by identifying new partners.
• Woulgan® – expansion of portfolio to be launched after 2019.

TekBot · mai 9, 2019, 1:30pm

09/05-2019 15:30:00: (BIOTEC) Biotec Pharmacon will present at Anglonordic Life Science Conference

BioMed · mai 11, 2019, 4:56pm

Kronn · mai 12, 2019, 5:51am

TekBot · mai 15, 2019, 11:34am

15/05-2019 13:33:52: (BIOTEC) Biotec Pharmacon - Minutes from Annual General Meeting

Savepig · juli 4, 2019, 11:19am

Not.

Safe.

For.

Life.

TekBot · august 8, 2019, 10:15am

Biotec Pharmacon ASA: Invitation to presentation of Q2 2019 results

TekBot · august 15, 2019, 5:00am

Biotec Pharmacon Q2 2019 Presentation

Savepig · august 15, 2019, 11:20am

Ser absolutt ut som om de trender riktig vei?

Både Q1 og Q2 kvartalsvis vekst fra i fjor

Kronn · august 15, 2019, 11:46am

Eg er sikker på at biotec kommer etterhvert, eg sitter med en bøtte med snitt like over 4, noe eg har en sterk tro på vil kunne gi en fin avkastning etterhvert, men trolig ikke med det første.
Eg mener biotec med sin lave mcap kan være verdt å eie noen lodd i, for fremtiden

Kronn · august 21, 2019, 6:33pm

Da ble det omsider en positiv retning på kursen, føles godt når man har sittet å småplukket rundt 4kr over lang tid på lav oms, når den da bykser opp som idag, så smaker det godt, måtte den holde seg oppe og ikke falle nedigjen

FiloD · august 21, 2019, 7:13pm

Jeg ønsker dere lykke til, det fortjener dere trofaste aksjonærer. Og jeg er også ganske sikker på at Jürgensen nu har fået det vendt.

Savepig · august 21, 2019, 7:30pm

Ja hvis de fortsetter å trende positivt så er ihvertfall jeg interessert. Men må sette meg mer inn i selskapet, aner ingenting om hverken markedet de er i eller teamet de sitter på nå. Har vært litt turbulent der?